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Background: INSTIs have become a pillar of first-line ART. Real-world data are needed to assess their effective-
ness in routine care.
Objectives: We analysed ART-naive patients who started INSTI-based regimens in 2012–19 whose data were
collected by INTEGRATE, a European collaborative study including seven national cohorts.
Methods: Kaplan–Meier analyses assessed time to virological failure (VF), defined as one viral load (VL)
1000 copies/mL, two consecutive VLs50 copies/mL, or one VL50 copies/mL followed by treatment change
after 24 weeks of follow-up, and time to INSTIs discontinuation (INSTI-DC) for any reason. Factors associated
with VF and INSTI-DC were explored by logistic regression analysis.
Results: Of 2976 regimens started, 1901 (63.9%) contained dolutegravir, 631 (21.2%) elvitegravir and 444
(14.9%) raltegravir. The 1 year estimated probabilities of VF and INSTI-DC were 5.6% (95% CI 4.5–6.7) and
16.2% (95% CI 14.9–17.6), respectively, and were higher for raltegravir versus both elvitegravir and dolutegravir.
A baseline VL100 000 copies/mL [adjusted HR (aHR) 2.17, 95% CI 1.55–3.04, P < 0.001] increased the risk of VF,
while a pre-treatment CD4 count 200 cells/mm3 reduced the risk (aHR 0.52, 95% CI 0.37–0.74, P < 0.001).
Predictors of INSTI-DC included use of raltegravir versus dolutegravir (aHR 3.03, 95% CI 2.34–3.92, P < 0.001), use
of >3 drugs versus 3 drugs (aHR 2.73, 95% CI 1.55–4.79, P < 0.001) and starting ART following availability of dolu-
tegravir (aHR 0.64, 95% CI 0.48–0.83, P = 0.001). Major INSTI mutations indicative of transmitted drug resistance
occurred in 2/1114 (0.2%) individuals.
Conclusions: This large multi-cohort study indicates high effectiveness of elvitegravir- or dolutegravir-based
first-line ART in routine practice across Europe.
Introduction
ART confers substantial clinical benefits by drastically reducing
HIV-related mortality and morbidity as well as improving the qual-
ity of life of people living with HIV, although eradication of HIV
infection cannot be achieved.1,2 Plasma HIV-1 RNA suppression
also prevents transmission, reduces the risk of drug resistance and
restores immunological function, reducing inflammation, immune
activation and premature ageing.3,4
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Integrase strand transfer inhibitor (INSTI)-based regimens are
preferred for first-line ART, reflecting safety and efficacy demon-
strated in clinical trials.5–7 Two first-generation INSTIs (raltegravir
and elvitegravir) and three second-generation INSTIs (dolutegra-
vir, bictegravir and cabotegravir) have been approved.8,9
Cabotegravir is administered as a once-monthly or bi-monthly, in-
jectable, long-acting drug, in combination with rilpivirine.10
While randomized trials and small observational studies have
demonstrated high virological efficacy, low risk of adverse events
and low rates of discontinuation of INSTI-based regimens, there
remains a need to monitor effectiveness on a large scale in real-
life settings. In addition, in the context of increasing use, there is a
need to monitor both treatment-emergent and transmitted drug
resistance (TDR) to INSTIs.11–17 The aim of this study was to deter-
mine the effectiveness of INSTI-based first-line ART across Europe,
as measured by the rate of virological failure (VF) and INSTIs dis-
continuation (INSTI-DC) for any cause, and to investigate potential
predictors of either outcome.
Methods
Study population
INTEGRATE is a large European collaboration enrolling HIV-1-positive indi-
viduals who started INSTI-based regimens at multiple clinical centres coor-
dinated by the EuResist Network (https://www.euresist.org/integrate). We
queried the EuResist integrated database to select ART-naive adults
(18 years) who had started raltegravir, elvitegravir or dolutegravir as part
of their first-line regimen between January 2012 and September 2019.
Individuals were excluded if lacking a pre-treatment genotypic drug resist-
ance test covering protease (PR) and reverse transcriptase (RT), or at least
one plasma HIV-1 RNA measurement after 24 weeks of follow-up.
The pre-treatment integrase genotype was also collected when available.
Data collection in different cohorts was fully anonymized and performed in
accordance with local regulations and approved by the local Ethics
Committees as required. Informed consent was obtained from participat-
ing individuals in accordance with all relevant regulations. The study was
performed in accordance with the Declaration of Helsinki (seventh revision)
and the International Conference on Harmonization Good Clinical Practice
guidelines.
Drug resistance
Genotypic resistance was determined by Sanger population sequencing
using commercially available or homebrew systems as available at each
participating centre. Drug resistance mutations indicative of TDR for NRTIs,
NNRTIs, PIs and INSTIs were defined based on reference lists (https://hivdb.
stanford.edu/pages/surveillance.html) using HIVdb version 8.8. Viral sub-
type was determined using the REGA 3.0 subtyping tool (http://dbpartners.
stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/).18,19
Statistical analysis
The objective of the analysis was to assess INSTI effectiveness, as defined
by the primary endpoint of virological outcome and the secondary endpoint
of durability. VF was defined as a single viral load 1000 copies/mL, two
consecutive viral loads50 copies/mL, or a single viral load50 copies/mL
followed by treatment change after 24 weeks of follow-up. The second-
ary outcome was defined as discontinuation for any reason of the INSTIs
included in the first-line ART regimen (INSTI-DC). Changing any companion
drug while maintaining the initial INSTI, or switching from a multiple to sin-
gle-tablet regimen or vice versa while maintaining the same components
of the regimen were not classified as discontinuation. Descriptive statistics
were used to illustrate the individuals’ baseline characteristics. Baseline
was defined as the INSTI start date. Differences between categorical varia-
bles were tested by v2 test and those between continuous variables were
tested by ANOVA. Kaplan–Meier analysis was used to determine the time to
VF and to INSTI-DC and differences between Kaplan–Meier curves were
evaluated by log-rank test. Cox regression models were used, after evaluat-
ing proportional hazard assumptions, to assess factors associated with VF
and INSTI-DC. Each variable was included in univariable models and then
the statistically significant variables (P < 0.05) were fitted simultaneously in
a multivariable model. Individuals were censored at event, VF, or INSTI-DC,
according to outcome, or at final follow-up, defined as last clinical visit,
drop-out date, or date of death. In all models, an unknown category was
used to account for missing data for categorical variables. Analyses were
performed using R open source statistical environment v. 3.6.3.20 All P val-




A total of 2976 ART-naive individuals were included, of whom
1901 (63.9%) started dolutegravir, 631 (21.2%) elvitegravir and
444 (14.9%) raltegravir between 2012 and 2019 (median 2016)
(Table S1, available as Supplementary data at JAC Online).
Baseline demographic and clinical characteristics are detailed in
Table 1. The cohort was diverse both in terms of HIV-1 subtypes
and risk groups. Notably, individuals in the raltegravir group had
higher baseline viral load and lower CD4 cell counts with respect to
the elvitegravir and dolutegravir groups. The vast majority of indi-
viduals received 3 drugs (94.5%) while low proportions received <3
drugs (1.4%) and >3 drugs (4.1%). Companion drugs included
NRTIs in 99.1% of patients, PIs in 4.8%, NNRTIs in 0.6% and the
entry inhibitors maraviroc or enfuvirtide in 0.5%. Among 43 individ-
uals treated with <3 drugs, 25 (58.1%) started raltegravir (n = 14)
or dolutegravir (n = 11) plus a PI and 15 (34.9%) started dolutegra-
vir ! lamivudine or emtricitabine or tenofovir disoproxil fumarate,
whereas 3 (7.0%) received other two-drug combinations. Among
the 122 individuals treated with >3 drugs, 103 (84.5%) received
a PI, mainly boosted darunavir with raltegravir (62, 60.1%) and
dolutegravir (25, 24.3%) and boosted atazanavir with raltegravir
(8, 7.8%).
Drug resistance
PR and RT genotype before introduction of INSTI-containing regi-
men were available for all participants as per inclusion criteria,
whereas integrase genotype was available in 1019 individuals
(34.2%). The overall prevalence of any TDR was 9.6%. In particular,
NRTI, NNRTI, PI and INSTI resistance mutations were detected in
117 (3.9%), 136 (4.6%), 72 (2.4%) and 2 (0.2%) individuals, re-
spectively. The most common TDR mutations detected were the
thymidine analogue mutations (TAMs) T215rev (n = 58; 1.9%) and
M41L (n = 40, 1.3%), M184IV (n = 26; 0.9%) for NRTIs, K103NS
(n = 86; 2.9%) for NNRTIs and M46I/L (n = 25; 0.8%) for PIs. The two
INSTI TDR cases showed R263K in one and N155H in the other,
both without contemporary resistance detected to other classes.
Virological outcomes and risk factors for VF
During 3520 person-years of follow-up (PYFU), VF occurred in 169
individuals with an estimated cumulative probability at 1 year of
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5.6% (95% CI 4.5–6.7). Individuals treated with raltegravir showed
a significantly higher estimated probability of 1 year VF (9.0%, 95%
CI 4.9–12.9) versus both elvitegravir (5.2%, 95% CI 3.0–7.4) and
dolutegravir (5.1%, 95% CI 3.8–6.5) (P by log-rank test = 0.007)
(Figure 1a). In the regression model, a pre-treatment viral load
100000 copies/mL increased the risk of VF with an adjusted HR
(aHR) of 2.17 (95% CI 1.55–3.04, P < 0.001), whereas a pre-treat-
ment CD4 count 200 cells/mm3 reduced the risk (aHR 0.52, 95%
CI 0.37–0.74, P < 0.001) after adjusting for time-dependent avail-
ability of raltegravir, elvitegravir and dolutegravir, number of drugs
co-administered, type of INSTI, NRTI or PI including regimen. In a
separate analysis, TDR for at least one class had no impact on VF
(Table S2). VFs according to study definitions across the different
treatment groups are detailed in Table S3.
Durability and risk factors for INSTIs-DC
During 8780 PYFU, INSTI-DC occurred in 800 individuals with an
estimated cumulative probability at 1 year of 16.2% (95% CI 14.9–
17.6). Individuals treated with raltegravir showed a significantly
higher estimated probability of 1 year INSTI-DC (39.9%, 95% CI
35.1–44.3) versus both elvitegravir (12.8%, 95% CI 10.2–15.4) and
dolutegravir (11.8%, 95% CI 10.4–13.3) (P by log-rank test <0.001)
(Figure 1b). Among 708 individuals with known viral load at the
time of INSTI-DC, 241 (34%) showed a viral load 50 copies/mL
[103/1901 (5.4%) with dolutegravir, 92/444 (20.7%) with raltegra-
vir and 46/631 (7.3%) with elvitegravir] whilst 467 (66%) showed a
viral load <50 copies/mL [203/1901 (10.7%) with dolutegravir,
178/444 (40.1%) with raltegravir and 86/631 (13.6%) with elvite-
gravir]. In the regression analysis, after adjusting for pre-treatment
viral load and CD4 cell counts, inclusion of NNRTI or PI or entry
inhibitors in the regimen, and TDR for at least one class, INSTI-DC
was associated with use of raltegravir versus dolutegravir (aHR
3.03, 95% CI 2.34–3.92, P < 0.001), use of >3 drugs versus 3 drugs
(aHR 2.73, 95% CI 1.55–4.79, P < 0.001) and starting ART after ver-
sus before dolutegravir availability (aHR 0.64, 95% CI 0.48–0.83,
P = 0.001); there was evidence to suggest that the time-dependent
availability of dolutegravir, elvitegravir and raltegravir modulated
the likelihood of INSTI-DC (Table S4). INSTI-DCs across the differ-
ent treatment groups are detailed in Table S3.
Table 1. Baseline characteristics of population
Total population
(N = 2976)






(n = 444) P value
Age (years), median (IQR) 39 (31–48) 39 (31–48) 38 (30–45) 40 (32–49) 0.001*
Female gender, n (%) 629 (21.1) 442 (23.3) 73 (11.6) 114 (25.7) <0.001*
Non-B viral subtype, n (%) 1369 (46.0) 861 (45.3) 450 (71.3) 252 (56.8) <0.001**
Risk factor, n (%) <0.001*
MSM 1183 (39.8) 700 (36.8) 316 (50.1) 167 (37.6)
heterosexual contacts 867 (29.1) 614 (32.3) 128 (20.3) 125 (28.2)
injecting drug users 119 (4.0) 84 (4.4) 19 (3.0) 16 (3.6)
other/unknown 807 (27.1) 503 (26.5) 168 (26.6) 136 (30.6)
Non-Caucasian ethnicity, n (%) 602 (20.2) 463 (24.4) 68 (10.8) 71 (16.0) <0.001**
Calendar year of HIV diagnosis, median (IQR) 2016 (2014–17) 2016 (2015–17) 2014 (2013–16) 2013 (2012–15) <0.001**
Calendar year of therapy start, median (IQR) 2016 (2015–17) 2016 (2015–17) 2016 (2014–17) 2014 (2013–15) <0.001**
Baseline HIV-1 RNA, log10 copies/mL,
median (IQR)
5.0 (4.4–5.6) 4.9 (4.3–5.5) 4.7 (4.1–5.2) 5.1 (4.3–5.8) <0.001**
Baseline HIV-1 RNA100 000 copies/mL, n (%) 1422 (47.8) 924 (48.6) 237 (37.6) 261 (58.8) <0.001**
Baseline CD4 cell count (cells/mm3),
median (IQR)
323 (148–498) 310 (128–490) 368 (258–539) 272 (104–510) <0.001**
Baseline CD4 cell count <200 cells/mm3, n (%) 865 (29.1) 596 (31.4) 110 (17.4) 159 (35.8) <0.001**
NRTI, n (%) 2949 (99.1) 1890 (99.4) 631 (100) 428 (96.4) <0.001***
TDF or TAF ! 3TC or FTC 1897 (64.3) 914 (48.4) 631 (100) 352 (82.2) <0.001**
ABC ! 3TC 1012 (34.3) 955 (50.5) 0 57 (13.3) <0.001**
others 40 (1.4) 21 (1.1) 0 19 (4.4) <0.001**
NNRTI, n (%) 17 (0.6) 4 (0.2) 0 13 (2.9) <0.001***
PI, n (%) 143 (4.8) 35 (1.8) 2 (0.3) 106 (23.9) <0.001***
EI, n (%) 15 (0.5) 4 (0.2) 0 11 (2.5) <0.001***
ABC, abacavir; DTG, dolutegravir; EI, entry inhibitor; EVG, elvitegravir; FTC, emtricitabine; NRTI, nucleos(t)ide reverse transcriptase inhibitor; RAL, ralte-
gravir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine.
*Statistically significant for dolutegravir versus elvitegravir and elvitegravir versus raltegravir.
**Statistically significant for all comparisons between drugs.
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Discussion
This large European multi-cohort study provides real-world evidence
for the high efficacy and durability of INSTI-based first-line ART regi-
mens started between 2012 and 2019 in Europe, highlighting a
greater virological efficacy and durability of elvitegravir- or dolute-
gravir-based regimens compared with those based on raltegravir.
The three INSTI treatment groups differed in most of their
baseline characteristics. Individuals receiving elvitegravir were
younger and more frequently males than those receiving other
INSTIs. Non-B viral subtypes were well represented in the whole
dataset, but significantly more prevalent in the elvitegravir group
with respect to the others. HIV acquisition risk was also associated
Figure 1. Kaplan–Meier curves showing virological failure according to INSTIs (a) and INSTIs discontinuation (b). DTG, dolutegravir; EVG, elvitegravir;
RAL, raltegravir.
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with treatment group, with MSM more likely to receive elvitegravir
than heterosexual participants. As expected, the use of the differ-
ent INSTIs was affected by the sequential availability of raltegravir
first, then elvitegravir and finally dolutegravir. The higher baseline
CD4 cell counts in the dolutegravir and elvitegravir groups versus
raltegravir group probably reflects the sequential availability of the
three INSTIs in a large observational time together with the
increasing trend in recent years to start ART at earlier stages of in-
fection, following the demonstration of improved clinical outcome
and reduced transmission of infection.1,2 Given the need for life-
long treatment, current availability of more treatment options led
to an optimized sequential INSTIs use, considering drug–drug
interactions, pre-existing resistance-associated mutations and
clinical setting of ART initiation.
Consistent with common understanding, 5–7,21 a higher pre-
treatment viral load and lower pre-treatment CD4 cell count were
associated with an increased risk of VF after starting first-line ART
with an INSTI-based regimen. Interestingly, the impact of higher
pre-treatment viral load was confirmed even among those treated
with dolutegravir- or elvitegravir-including regimens (data not
shown), without any effect of the specific NRTI backbone among
those receiving a dolutegravir-based ART regimen.
INSTIs were primarily used in accordance with standard
practice, with the vast majority of individuals receiving an INSTI in
combination with two NRTIs. The NRTI backbones associated with
the different INSTIs reflected the availability of elvitegravir- and
dolutegravir-based single-tablet regimens, but there was no sig-
nificant impact of the different NRTI backbones on the outcome
measures. A minority of patients received less common regimens,
including two-drug combinations or combinations including more
than three agents. As expected, the latter presented at baseline
higher viral load (5.9 copies/mL, IQR 5.3–6.5) and more frequently
carried TDR; NNRTI-TDR was reported in 8.2% and NRTI-TDR in
4.9%, corresponding to 10 and 6 cases, respectively. Regimens
including >3 drugs were associated with an increased likelihood
of subsequent INSTI-DC. Overall, raltegravir was discontinued
more often than elvitegravir and dolutegravir, likely reflecting the
earlier availability of raltegravir, the lack of raltegravir-including
fixed-dose combinations and the twice-daily administration of this
drug at least in the earlier treatments. The effect of this last poten-
tial confounder was not measurable due to a lack of information
regarding raltegravir posology. Interestingly, the rates of discon-
tinuation were not different for elvitegravir- versus dolutegravir-
based INSTI regimens, despite the higher genetic barrier of the lat-
ter and the higher potential for drug–drug interactions with
boosted elvitegravir-including regimens. It is possible that the
mandatory use of elvitegravir as single-tablet regimen made elvi-
tegravir as effective as dolutegravir, which was used in mixed for-
mulations, both as a single agent and in fixed-dose combination
with abacavir and lamivudine. Unfortunately, this information was
not available in the case file.
Based on current reported rates of TDR to different antiretrovi-
rals, current international guidelines recommend genotypic
drug-resistance testing in ART-naive persons focusing on testing
for mutations in the RT and PR genes.5–7 There is no recommenda-
tion for baseline integrase sequencing as transmission of INSTI
resistance-associated mutations remains anecdotal. In this study,
136 (4.6%) patients started an INSTI-based regimen in the pres-
ence of pre-treatment resistance, most frequently TAMs, but this
did not impact on virological efficacy, similarly to previous studies
enrolling individuals with pre-treatment resistance.17 First-gener-
ation INSTIs (raltegravir and elvitegravir) have been used earlier
and for longer than dolutegravir in PLWH and are more likely to se-
lect for INSTI resistance at VF due to their low genetic barrier. By
contrast, dolutegravir and the other second-generation bictegravir
have a much higher genetic barrier, thus their use should further
limit both selection and transmission of INSTIs resistance.
The strengths of the study are the large number of individuals,
the international representativeness of the real-life setting and the
enrolment of individuals typically not included in randomized trials
due to the presence of baseline resistance. Another advantage is
the wide calendar time span analysed, encompassing years 2012–
19 and including 8780 PYFU. The main limitations are the lack of
detailed information on the reason for INSTI-DC and on adherence
to treatment, the relatively small number of individuals with the
pre-treatment integrase genotype and the lack of genotypic data
at VF. Finally, female gender of non-Caucasian ethnicity was poorly
represented, being only one-fifth of the general population and
just over one-tenth of the patients treated with elvitegravir. As
with any observational study, our analysis may be affected by un-
measured potential confounders as the choice of ART drugs is
influenced by many factors, including co-morbidities or concomi-
tant medications.
In conclusion, INSTI-based antiretroviral regimens are effective
for first-line ART, even in presence of TDR for the accompanying
drugs. However, the rate of discontinuation is much higher than
the rate of VF. Future analyses should expand the proportion of
cases with baseline integrase genotype, include bictegravir and
analyse the reasons for INSTI-DC to define the full potential of se-
cond-generation INSTI-based regimens in the clinical setting.
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